The purpose of this trial is to see if the drug ravulizumab is safe and effective in patients with thrombotic microangiopathy (TMA). This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug. You will recieve the drug or placebo for about 6 months and then have follow-up appoinments for about 6 months.
Inclusion Criteria
Exclusion Criteria
- History of cancer <5 years ago (with some exceptions)
- Known chronic kidney disease with estimated GFR <45 mL/min/1.73^2
Study Requirements
This study involves a screening visit, 13 visits during the 26 week treatment period, and 3 visits during the 26 week follow up period. Some study visits include blood draws and urine collections. No x-rays/CT scans/MRIs are required by the study.
